TY - JOUR
T1 - A better method for assessment of hepatic function in hepatocellular carcinoma patients treated with radiofrequency ablation
T2 - Usefulness of albumin–bilirubin grade
AU - On behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics)
AU - Hiraoka, Atsushi
AU - Kumada, Takashi
AU - Hirooka, Masashi
AU - Tsuji, Kunihiko
AU - Itobayashi, Ei
AU - Kariyama, Kazuya
AU - Ishikawa, Toru
AU - Tajiri, Kazuto
AU - Ochi, Hirofumi
AU - Tada, Toshifumi
AU - Toyoda, Hidenori
AU - Nouso, Kazuhiro
AU - Joko, Koji
AU - Kawasaki, Hideki
AU - Hiasa, Yoichi
AU - Michitaka, Kojiro
N1 - Publisher Copyright:
© 2017 The Japan Society of Hepatology
PY - 2018/2
Y1 - 2018/2
N2 - Aim: To evaluate the efficacy of the newly proposed albumin–bilirubin (ALBI) grade for therapy selection, clinical features of patients treated with radiofrequency ablation (RFA) were elucidated. Methods: From 2000 to 2015, 1101 patients with HCC (<3 cm, ≤3 tumors) treated with RFA were enrolled, with the following clinical features: 734 men and 367 women; 779 with hepatitis C virus, 153 with hepatitis B virus, 5 with hepatitis C and B, and 164 others; and Child–Pugh classification (CP) A : B ratio of 842:259. Liver damage classification (LD) using the indocyanine green retention rate at 15 min and ALBI-grade were compared in regard to the prognoses of those patients. Results: Median tumor size was 1.7 cm (interquartile range, 1.4–2.2 cm) and single tumors were found in 802 cases (72.8%) (tumor–node–metastasis stage of the Liver Cancer Study Group of Japan I : II : III = 536:454:111). In the LD-A group, the number of cases with ALBI-grade 1, 2, and 3 were 294, 224, and 1, respectively, while those in the LD-B group were 47, 490, and 12, respectively. In the LD-C group, 19 and 14 patients were ALBI-2 and -3, respectively. Akaike Information Criterion values for CP, LD-grade, and ALBI-grade were 6015.4, 5988.8, and 5990.7, respectively. However, there was no significant difference regarding prognosis between LD-A/B (n = 228) and C (n = 31) (median survival time, 4.8 vs. 3.9 years, P = 0.0818) in CP-B, whereas a significant difference was observed regarding prognosis for ALBI-1/2 (n = 232) and ALBI-3 (n = 27) (median survival time, 4.8 vs. 2.7 years, P = 0.0168). Conclusion: Albumin–bilirubin grade showed an assessment ability similar to that of LD-grade. Furthermore, there was a small improvement in prognosis following RFA in patients with an ALBI-grade of 3. Although only two serological parameters, albumin and total bilirubin, are used, assessment with ALBI-grade may be more useful than with LD-grade for avoiding a non-beneficial RFA procedure.
AB - Aim: To evaluate the efficacy of the newly proposed albumin–bilirubin (ALBI) grade for therapy selection, clinical features of patients treated with radiofrequency ablation (RFA) were elucidated. Methods: From 2000 to 2015, 1101 patients with HCC (<3 cm, ≤3 tumors) treated with RFA were enrolled, with the following clinical features: 734 men and 367 women; 779 with hepatitis C virus, 153 with hepatitis B virus, 5 with hepatitis C and B, and 164 others; and Child–Pugh classification (CP) A : B ratio of 842:259. Liver damage classification (LD) using the indocyanine green retention rate at 15 min and ALBI-grade were compared in regard to the prognoses of those patients. Results: Median tumor size was 1.7 cm (interquartile range, 1.4–2.2 cm) and single tumors were found in 802 cases (72.8%) (tumor–node–metastasis stage of the Liver Cancer Study Group of Japan I : II : III = 536:454:111). In the LD-A group, the number of cases with ALBI-grade 1, 2, and 3 were 294, 224, and 1, respectively, while those in the LD-B group were 47, 490, and 12, respectively. In the LD-C group, 19 and 14 patients were ALBI-2 and -3, respectively. Akaike Information Criterion values for CP, LD-grade, and ALBI-grade were 6015.4, 5988.8, and 5990.7, respectively. However, there was no significant difference regarding prognosis between LD-A/B (n = 228) and C (n = 31) (median survival time, 4.8 vs. 3.9 years, P = 0.0818) in CP-B, whereas a significant difference was observed regarding prognosis for ALBI-1/2 (n = 232) and ALBI-3 (n = 27) (median survival time, 4.8 vs. 2.7 years, P = 0.0168). Conclusion: Albumin–bilirubin grade showed an assessment ability similar to that of LD-grade. Furthermore, there was a small improvement in prognosis following RFA in patients with an ALBI-grade of 3. Although only two serological parameters, albumin and total bilirubin, are used, assessment with ALBI-grade may be more useful than with LD-grade for avoiding a non-beneficial RFA procedure.
KW - ALBI grade
KW - Child–Pugh
KW - ICG
KW - hepatocellular carcinoma
KW - liver damage
KW - radiofrequency ablation
UR - http://www.scopus.com/inward/record.url?scp=85026639081&partnerID=8YFLogxK
U2 - 10.1111/hepr.12927
DO - 10.1111/hepr.12927
M3 - 学術論文
C2 - 28628718
AN - SCOPUS:85026639081
SN - 1386-6346
VL - 48
SP - E61-E67
JO - Hepatology Research
JF - Hepatology Research
IS - 3
ER -